Mode
Text Size
Log in / Sign up
Phase 2 N=14 Randomized Triple-blind

Thyroid and Glucose and Energy Metabolism

Thyroid Diseases

Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Feb 2015
Primary outcome: Primary: Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase — 7.26 mg/kg/min

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Liothyronine and Levothyroxine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary completion
Nov 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase
7.26
PRIMARY
Insulin-mediated Glucose Disposal Rate at Liothyronine Treatment Phase
7.37
SECONDARY
Total Cholesterol at Levothyroxine Treatment Phase
196
SECONDARY
Total Cholesterol at Liothyronine Treatment Phase
174
SECONDARY
Triglycerides at Levothyroxine Treatment Phase
152
SECONDARY
Triglycerides at Liothyronine Treatment Phase
144
SECONDARY
Resting Energy Expenditure at Levothyroxine Treatment Phase
1201
SECONDARY
Resting Energy Expenditure at Liothyronine Treatment Phase
1177
SECONDARY
Left Ventricle Mass Index at Levothyroxine Treatment Phase
71
SECONDARY
Left Ventricle Mass Index at Liothyronine Treatment Phase
71
SECONDARY
Apolipoprotein A-I at Levothyroxine Treatment Phase
152
SECONDARY
Apolipoprotein A-I at Liothyronine Treatment Phase
144
SECONDARY
Apolipoprotein B at Levothyroxine Treatment Phase
87
SECONDARY
Apolipoprotein B at Liothyronine Treatment Phase
72

Summary

This study will examine how two thyroid preparations-levothyroxine (T4) and liothyronine (T3)-affect fat and cholesterol metabolism, blood sugar regulation, and thyrotropin secretion in patients who have had their thyroid gland removed. Results of the study may help in the development of better therapies to optimize blood sugar and cholesterol levels in some patients. Patients 18 years of age or older who have had most or all of their thyroid gland removed and are taking long-term thyroid hormone medication may be eligible for this study after screening.

Eligibility Criteria

  • INCLUSION CRITERIA:

Age greater than or equal to 18 years, male or female.

History of total or near total thyroidectomy or hypothyroidism on replacement therapy.

For non-thyroidectomized patients, at least three-year history of replacement therapy (at least 1.2 mcg/Kg LT4/body weight), and less than 5% uptake at 24H on (123)I thyroid scan while on replacement therapy.

Written informed consent.

EXCLUSION CRITERIA

BMI less than or equal to 20 or greater than or equal to 30 kg/m(2).

Metastatic thyroid cancer or history of thyroid cancer with high risk of recurrence requiring suppressive thyroid hormone therapy (Singer 1996).

Significant thyroid residual greater than 1 mL as measured by ultrasound (limited to thyroidectomized patients) or greater than 5 percent uptake at 24H on (123)I thyroid scan while on replacement therapy (limited to hypothyroid patients not undergone total thyroidectomy).

History or symptoms compatible with cardiovascular disease, including paroxysmal supraventricular tachycardia, atrial fibrillation, syncopal episodes or use of prescription medications for heart conditions, including antihypertensives.

Allergy to lidocaine, isoproterenol, TRH, levothyroxine, liothyronine, Tylenol #3, oxycodone, nitroglycerin.

Pregnancy or unwillingness to use non-hormonal contraception during the study.

Breastfeeding

Use of hormonal contraceptives or estrogen replacement therapy.

Use of tobacco (smoking, chewing) for the two weeks preceding the hospital admissions (metabolic testing)

Diabetes mellitus, either type I or II.

Hypercholesterolemia (serum levels greater than or equal to 240 mg/dL), hypertriglyceridemia (plasma levels greater than or equal to 220 mg/dL) and/or use of antilipemic therapy.

Liver disease or ALT serum level greater than two fold the upper laboratory reference limit.

Renal insufficiency or estimated creatinine clearance less than or equal to 50 mL/min.

Use of medications/supplements/alternative therapies known to alter thyroid function.

Current history or symptoms compatible with psychosis including major depression (including history of hospitalization for depression, history of attempted suicide, history of suicidal ideation).

Use of antipsychotic medications

History of drug or alcohol abuse within the last 5 years; current use of drugs or alcohol (CAGE greater than 3).

Keloid formation (relative to skeletal muscle and subcutaneous adipose tissue biopsies).

Current or previous clinically significant (requiring medical/surgical intervention) extrathyroidal manifestations of autoimmune thyroid disease (dermopathy, ophthalmopathy, arthropathy).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00106119). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search